Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES BAIN CAPITAL AND BRAVIDA
Mandate

VINGE ADVISES BAIN CAPITAL AND BRAVIDA

June 20, 2013

Vinge and Kirkland & Ellis are advising Bain Capital and Bravida in connection with the refinancing of Bravida, which includes the issue of senior secured floating rate notes in the amount of SEK 1.3 billion and EUR 225 million.

Vinge’s team consists of partners Stefan de Hevesy, Christina Kokko and Peter Bäärnhielm together with associates Robin Dangoor, Paul Dali, Charlotta Järnstedt, Andreas Malmberg, Dain Nevonen and Marie Brommesson.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

 Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024